Phaos Technology Holdings (Cayman) (POAS) Debt to Equity (2024 - 2025)

Phaos Technology Holdings (Cayman) (POAS) reported Debt to Equity of -$0.03 for Q4 2025, up 55.06% quarter-over-quarter from -$0.07 in Q2 2025.

Phaos Technology Holdings (Cayman) (POAS) Debt to Equity (2024 - 2025) Analysis & Trends

Phaos Technology Holdings (Cayman) has reported Debt to Equity for 2 years, with the latest figure at -$0.03 in Q4 2025.

For the quarter ending Q4 2025, Debt to Equity changed N/A year-over-year to -$0.03; the trailing twelve-month figure through Oct 2025 stood at -$0.03 (changed N/A YoY), and the FY2025 full-year result was -$0.07, down 134.7% from the prior year.
Debt to Equity for Q4 2025 stood at -$0.03, up from -$0.07 in the prior quarter.
The five-year high for Debt to Equity was $0.2 in Q2 2024, with the low at -$0.07 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.65
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.64
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.57
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.06
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.71
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.95
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.27
10	Phaos Technology Holdings (Cayman)	682,234.12	627,245.12	-	-0.03

Download Data